Deferasirox Sprinkle Granules and Urokinase Intravenous
Determining the interaction of Deferasirox Sprinkle Granules and Urokinase Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using deferasirox together with urokinase may increase the risk of gastrointestinal ulcers and bleeding. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you experience potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, loss of appetite, nausea, vomiting (especially with fresh or dried blood that looks like coffee grounds), and red or black, tarry stools. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR CLOSELY: Coadministration with drugs that have known ulcerogenic or hemorrhagic potential may increase the risk of gastrointestinal bleeding associated with the use of deferasirox. Fatal gastrointestinal hemorrhages have been reported during deferasirox therapy, especially in elderly patients with advanced hematologic malignancies and/or low platelet counts. Nonfatal upper gastrointestinal irritation, ulceration, and hemorrhage have also been reported, including in children and adolescents.
MANAGEMENT: Caution is advised if deferasirox is prescribed with drugs that have known ulcerogenic or hemorrhagic potential, including but not limited to NSAIDs, salicylates, corticosteroids, oral bisphosphonates, platelet inhibitors, anticoagulants, thrombolytic agents, or agents that commonly cause thrombocytopenia. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, hematemesis, anorexia, and/or black, tarry stools.
- "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: deferasirox
Brand name: Exjade, Jadenu, Jadenu Sprinkle
Synonyms: Deferasirox
Generic Name: urokinase
Brand name: Kinlytic, Abbokinase, Abbokinase Open-Cath
Synonyms: Urokinase
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Deferasirox Sprinkle Granules-Urolet MB
- Deferasirox Sprinkle Granules-Urophen MB
- Deferasirox Sprinkle Granules-Uroxatral
- Deferasirox Sprinkle Granules-Urso
- Deferasirox Sprinkle Granules-Urso 250
- Deferasirox Sprinkle Granules-Urso Forte
- Urokinase Intravenous-Deferasirox Tablets
- Urokinase Intravenous-Deferasirox Tablets For Oral Suspension
- Urokinase Intravenous-Deferiprone
- Urokinase Intravenous-Deferiprone Oral Solution
- Urokinase Intravenous-Deferiprone Tablets
- Urokinase Intravenous-Deferoxamine